keyword
MENU ▼
Read by QxMD icon Read
search

Formoterol

keyword
https://www.readbyqxmd.com/read/29906501/repurposing-drugs-as-inhaled-therapies-in-asthma
#1
Sandra D Anderson
For the first 40 years of the 20th century treatment for asthma occurred in response to an asthma attack. The treatments were given by injection or orally and included the adrenergic agonists adrenalin/epinephrine and ephedrine and a phosphodiesterase inhibitor theophylline. Epinephrine became available as an aerosol in 1930. After 1945, isoprenaline, a non-selective beta agonist, became available for oral use but it was most widely used by inhalation. Isoprenaline was short-acting with unwanted cardiac effects...
June 12, 2018: Advanced Drug Delivery Reviews
https://www.readbyqxmd.com/read/29905977/inspiromatic-safety-and-efficacy-study-of-a-new-generation-dry-powder-inhaler-in-asthmatic-children
#2
Guy Steuer, Dario Prais, Huda Mussaffi, Meir Mei-Zahav, Ophir Bar-On, Hagit Levine, Yulia Gendler, Hannah Blau, Patrick Stafler
BACKGROUND: Dry powder inhalers (DPI) are effective but forceful inhalation required to fluidize the powder may be difficult for children and patients with airway disease. Inspiromatic is a new generation active DPI that actively suspends drugs in synchrony with inhalation. We evaluated safety and efficacy of Formoterol delivery via Inspiromatic, compared to Aerolizer, a conventional DPI, in pediatric asthmatic subjects. METHODS: A phase I/II, randomized, single-center, double-blind, double-dummy, placebo-controlled, cross-over study...
June 15, 2018: Pediatric Pulmonology
https://www.readbyqxmd.com/read/29901860/pharmacokinetics-of-co-suspension-delivery-technology-budesonide-glycopyrronium-formoterol-fumarate-dihydrate-bgf-mdi-and-budesonide-formoterol-fumarate-dihydrate-bff-mdi-fixed-dose-combinations-compared-with-an-active-control-a-phase-1-randomized-single-dose
#3
Andrea Maes, Paolo DePetrillo, Shahid Siddiqui, Colin Reisner, Paul Dorinsky
This randomized, phase 1, single-dose, crossover study (NCT02189304) compared the 12-hour pharmacokinetic (PK) and safety profiles of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) 320/14.4/10 μg and budesonide/formoterol fumarate dihydrate (BFF) MDI 320/10 μg (both formulated using innovative co-suspension delivery technology) to an active comparator (budesonide/formoterol fumarate dihydrate dry powder inhaler [BUD/FORM DPI] 320/9-μg delivered dose) in healthy adults...
June 14, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29886657/-effect-of-long-term-asthma-management-on-asthma-patients-from-china-japan-friendship-hospital
#4
J T Lin, W Q Wang, C Y Han, L Yan, B Xing, R F Qiu, H W Li, Y F Wang, L Li, X Y Li, M Y Zhang
Objective: To investigate the outcome of long-term asthma management of China-Japan Friendship Hospital. Methods: A face-to-face, questionnaire-based survey was carried out in outpatient department in 30 general hospital (including China-Japan Friendship Hospital) from Oct 2015 to May 2016. Data of demographic characteristics, asthma control, asthma management, asthma attacks and self-management, disease perception was collected. Results from China-Japan Friendship Hospital were compared to the national mean level within the same period...
May 29, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29882826/a-muscarinic-antagonist-reduces-airway-inflammation-and-bronchoconstriction-induced-by-ambient-particulate-matter-in-a-mouse-model-of-asthma
#5
Jun Kurai, Masanari Watanabe, Hiroyuki Sano, Kyoko Iwata, Degejirihu Hantan, Eiji Shimizu
Ambient particulate matter (PM) can increase airway inflammation and induce bronchoconstriction in asthma. This study aimed to investigate the effect of tiotropium bromide, a long-acting muscarinic antagonist, on airway inflammation and bronchoconstriction induced by ambient PM in a mouse model of asthma. We compared the effect of tiotropium bromide to that of fluticasone propionate and formoterol fumarate. BALB/c mice were sensitized to ovalbumin (OVA) via the airways and then administered tiotropium bromide, fluticasone propionate, or formoterol fumarate...
June 6, 2018: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/29869050/cost-effectiveness-of-pharmacological-treatments-for-asthma-a-systematic-review
#6
REVIEW
Carlos E Rodriguez-Martinez, Monica P Sossa-Briceño, Jose A Castro-Rodriguez
OBJECTIVE: The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease. METHODS: A systematic review of the literature in seven electronic databases was conducted in order to identify all the available health economic evidence on alternative pharmacological treatments for asthma published up to April 2017...
June 4, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29857783/efficacy-and-safety-of-fluticasone-propionate-formoterol-fumarate-in-pediatric-asthma-patients-a-randomized-controlled-trial
#7
Anna Płoszczuk, Miroslava Bosheva, Kay Spooner, Tammy McIver, Sanjeeva Dissanayake
BACKGROUND: The efficacy and safety of fluticasone propionate/formoterol fumarate pressurized metered-dose inhaler (pMDI) (fluticasone/formoterol; Flutiform® ; 100/10 µg b.i.d.) was compared with fluticasone propionate (Flixotide® Evohaler® pMDI; 100 µg b.i.d.) and fluticasone/salmeterol (Seretide® Evohaler® pMDI; 100/50 µg b.i.d.) in a pediatric asthma population (EudraCT number: 2010-024635-16). METHODS: A double-blind, double-dummy, parallel group, multicenter study...
January 2018: Therapeutic Advances in Respiratory Disease
https://www.readbyqxmd.com/read/29851792/efficacy-of-budesonide-formoterol-and-tiotropium-combination-for-the-treatment-of-chinese-patients-with-chronic-obstructive-pulmonary-disease
#8
Jun-Fei Feng, Guo-Rong Ding, Yan-Zhong Xie, Dejun Zhao, Xuehui Wang
This study investigated the efficacy and safety of budesonide/formoterol (B/F) and tiotropium combination in the management of chronic obstructive pulmonary disease (COPD) in Chinese patients.Between January 2015 and November 2017, 113 eligible Chinese patients with COPD were included and divided into an intervention group and a control group. Sixty-three patients in the intervention group underwent B/F combined tiotropium, while 50 patients in the control group received tiotropium alone. The primary outcome was severity of dyspnea on exertion (DOE), measured by the 6-minute walk test (6MWT) scale...
June 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29796287/effect-of-adjusting-the-combination-of-budesonide-formoterol-on-the-alleviation-of-asthma-symptoms
#9
Ryosuke Souma, Kumiya Sugiyama, Hiroyuki Masuda, Hajime Arifuku, Kentaro Nakano, Hiroyoshi Watanabe, Tomoshige Wakayama, Shingo Tokita, Masamitsu Tatewaki, Hideyuki Satoh, Kenya Koyama, Yumeko Hayashi, Fumiya Fukushima, Hirokuni Hirata, Masafumi Arima, Kazuhiro Kurasawa, Takeshi Fukuda, Yasutsugu Fukushima
Background: The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient. Methods: Twenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity...
2018: Asthma Research and Practice
https://www.readbyqxmd.com/read/29782959/targeting-central-%C3%AE-2-receptors-ameliorates-streptozotocin-induced-neuroinflammation-via-inhibition-of-glycogen-synthase-kinase3-pathway-in-mice
#10
Nora O Abdel Rasheed, Nesrine S El-Sayed, Aiman S El-Khatib
Alzheimer's disease (AD) is portrayed by progressive cognitive decline and pathological deposition of amyloid plaques as well as neurofibrillary tangles. Most of AD cases are sporadic, resulting from overlap of various environmental and genetic factors. Intra-cerebroventricular injection of streptozotocin (STZ) leads to insulin resistance brain state accompanied by memory decline, oxidative stress, and neuro-degeneration which mimic the pathologies associated with sporadic Alzheimer's disease (SAD). In the current study, protective effects of formoterol in STZ-induced SAD were studied...
May 18, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29775687/effects-of-bronchodilation-on-biomarkers-of-peripheral-airway-inflammation-in-copd
#11
Pierachille Santus, Dejan Radovanovic, Susanna Mascetti, Alessia Pauletti, Vincenzo Valenti, Marco Mantero, Alberto Papi, Marco Contoli
Peripheral airway inflammation and dysfunction are key elements in the pathogenesis of COPD. The exhaled alveolar fraction of nitric oxide (CANO) is an indirect biomarker of lung peripheral inflammation. We tested whether inhaled long-acting bronchodilators (LABA) can affect CANO and we evaluated correlations with lung mechanics in patients with COPD. Two-centre, randomised, double blind, crossover study including COPD patients with moderate-to-severe airflow obstruction. Following a pharmacological washout, multi-flow exhaled fraction of NO (FENO), plethysmography, lung diffusion (DLCO), single breath nitrogen washout test and dyspnoea were measured in a crossover manner at baseline and 30, 60 and 180 minutes following administration of salmeterol (Sal) or formoterol fumarate (FF)...
May 15, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29773947/efficacy-safety-and-pharmacokinetics-of-budesonide-formoterol-fumarate-delivered-via-metered-dose-inhaler-using-innovative-co-suspension-delivery-technology-in-patients-with-moderate-to-severe-copd
#12
Edward M Kerwin, Thomas M Siler, Samir Arora, Patrick Darken, Earl Rose, Colin Reisner
Purpose: This study investigated the efficacy, safety, and pharmacokinetics of the inhaled corticosteroid/long-acting β2 -agonist fixed-dose combination budesonide/formoterol fumarate (BFF) metered dose inhaler (MDI), compared with the monocomponents budesonide (BD) MDI and formoterol fumarate (FF) MDI, in patients with moderate-to-severe COPD. Materials and methods: In this Phase IIb, randomized, double-blind, four-period, five-treatment, incomplete-block, crossover study (NCT02196077), all patients received BFF MDI 320/9...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29768149/inhaled-combined-budesonide-formoterol-as-needed-in-mild-asthma
#13
RANDOMIZED CONTROLLED TRIAL
Paul M O'Byrne, J Mark FitzGerald, Eric D Bateman, Peter J Barnes, Nanshan Zhong, Christina Keen, Carin Jorup, Rosa Lamarca, Stefan Ivanov, Helen K Reddel
BACKGROUND: In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a fast-acting β2 -agonist may be an alternative to conventional treatment strategies. METHODS: We conducted a 52-week, double-blind trial involving patients 12 years of age or older with mild asthma. Patients were randomly assigned to one of three regimens: twice-daily placebo plus terbutaline (0.5 mg) used as needed (terbutaline group), twice-daily placebo plus budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed (budesonide-formoterol group), or twice-daily budesonide (200 μg) plus terbutaline used as needed (budesonide maintenance group)...
May 17, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29768147/as-needed-budesonide-formoterol-versus-maintenance-budesonide-in-mild-asthma
#14
RANDOMIZED CONTROLLED TRIAL
Eric D Bateman, Helen K Reddel, Paul M O'Byrne, Peter J Barnes, Nanshan Zhong, Christina Keen, Carin Jorup, Rosa Lamarca, Agnieszka Siwek-Posluszna, J Mark FitzGerald
BACKGROUND: Patients with mild asthma often rely on inhaled short-acting β2 -agonists for symptom relief and have poor adherence to maintenance therapy. Another approach might be for patients to receive a fast-acting reliever plus an inhaled glucocorticoid component on an as-needed basis to address symptoms and exacerbation risk. METHODS: We conducted a 52-week, double-blind, multicenter trial involving patients 12 years of age or older who had mild asthma and were eligible for treatment with regular inhaled glucocorticoids...
May 17, 2018: New England Journal of Medicine
https://www.readbyqxmd.com/read/29763659/safety-and-pharmacokinetics-of-budesonide-glycopyrronium-formoterol-fumarate-dihydrate-metered-dose-inhaler-bgf-mdi-in-healthy-adult-subjects-of-japanese-descent
#15
Paul Dorinsky, Paolo DePetrillo, Shahid Siddiqui, Andrea Maes, Colin Reisner
INTRODUCTION: BGF MDI, a budesonide, glycopyrronium, and formoterol fumarate dihydrate triple fixed-dose combination metered dose inhaler formulated using co-suspension delivery technology, is currently in Phase III global development for chronic obstructive pulmonary disease. METHODS: This was a Phase I, randomized, double-blind, placebo-controlled, ascending-dose, crossover study to assess the safety and pharmacokinetic profiles of two doses of BGF MDI in healthy adult subjects of Japanese descent (NCT02197975)...
May 12, 2018: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29762864/population-pharmacokinetic-analysis-of-fluticasone-furoate-umeclidinium-vilanterol-via-a-single-inhaler-in-patients-with-copd
#16
Rashmi Mehta, Eleni Pefani, Misba Beerahee, Noushin Brealey, Helen Barnacle, Ruby Birk, Chang-Qing Zhu, David A Lipson
A population pharmacokinetic analysis was conducted from a subset of samples obtained from the Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy trial to characterize the pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol in patients with symptomatic COPD following treatment with fluticason furoate-umeclidinium-vilanterol combined in a single inhaler. This was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticason furoate-umeclidinium-vilanterol, 100 μg/62...
May 15, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29755809/a-12-week-randomized-parallel-group-phase-iii-study-comparing-the-efficacy-of-once-daily-budesonide-formoterol-turbuhaler-160-4-5-%C3%AE-g-d-with-twice-daily-budesonide-400-%C3%AE-g-d-during-the-step-down-period-in-well-controlled-asthma
#17
Narongwit Nakwan, Thitima Perkleang, Thanida Tamsawai, Pattarawadee Taptawee, Sirikade Usaha
OBJECTIVES: Budesonide/formoterol fumarate (BUD/FF) is recommended in the stepwise management of uncontrolled asthma, but data on a once-daily dose of this medication in a step-down period are lacking. We aimed to compare BUD/FF and BUD in terms of the changes in asthma control scores and lung functions. MATERIAL AND METHODS: This 12-week, randomized, parallel-group, single-center, open-label study was conducted in well-controlled asthmatic patients receiving twice-daily BUD/FF (160/4...
April 2018: Turkish Thoracic Journal
https://www.readbyqxmd.com/read/29750142/single-inhaler-triple-therapy-in-symptomatic-copd-patients-fulfil-subgroup-analyses
#18
David M G Halpin, Ruby Birk, Noushin Brealey, Gerard J Criner, Mark T Dransfield, Emma Hilton, David A Lomas, Chang-Qing Zhu, David A Lipson
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2 -agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD) and at risk of exacerbations. However, the benefits versus side-effects of triple inhaled therapy for COPD, based on distinct patient clinical profiles, are unclear. FULFIL, a phase III, randomised, double-blind study, compared 24 weeks of once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62...
April 2018: ERJ Open Research
https://www.readbyqxmd.com/read/29724397/randomized-study-of-the-effects-of-aerochamber-plus-%C3%A2-flow-vu-%C3%A2-on-the-efficacy-pharmacokinetics-and-safety-of-glycopyrronium-formoterol-fumarate-dihydrate-metered-dose-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease
#19
Faisal Fakih, Selwyn Spangenthal, Barry Sigal, Patrick Darken, Andrea Maes, Shahid Siddiqui, Michael Gillen, Colin Reisner, Ubaldo J Martin
OBJECTIVES: This study compared the efficacy, pharmacokinetics (PK), and safety of GFF MDI (Bevespi Aerosphere® ), a fixed-dose combination of glycopyrronium and formoterol fumarate dihydrate (14.4/10 μg) delivered by a metered dose inhaler (MDI) formulated using innovative co-suspension delivery technology, in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) with and without the Aerochamber Plus® Flow-Vu® valved holding chamber (VHC). METHODS: In this multicenter, open-label, crossover, Phase III study (NCT02454959), patients were randomized to receive GFF MDI 14...
May 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29724381/pulmonary-deposition-of-fluticasone-propionate-formoterol-in-healthy-volunteers-asthmatics-and-copd-patients-with-a-novel-breath-triggered-inhaler
#20
Dominik Kappeler, Knut Sommerer, Claudius Kietzig, Bärbel Huber, Jo Woodward, Mark Lomax, Prashant Dalvi
INTRODUCTION: A combination of fluticasone propionate/formoterol fumarate (FP/FORM) has been incorporated within a novel, breath-triggered device, named K-haler® . This low resistance device requires a gentle inspiratory effort to actuate it, triggering at an inspiratory flow rate of approximately 30 L/min; thus avoiding the need for coordination of inhalation with manual canister depression. The aim of the study was to evaluate total and regional pulmonary deposition of FP/FORM when administered via the K-haler device...
May 2018: Respiratory Medicine
keyword
keyword
15057
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"